Pembrolizumab improved progression-free survival (PFS) and overall survival (OS) over best supportive care in patients with advanced hepatocellular carcinoma (HCC), according to the phase III KEYNOTE-240* trial, supporting its role as a treatment option for HCC in the second-line setting.
Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 20190910083343
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
DOACs* were better than warfarin in terms of efficacy and safety for stroke prevention in an Asian population with atrial fibrillation (AF) and liver disease, including patients with significant active liver disease who were usually excluded from pivotal clinical trials, suggests a study based on the Korean national database.
New drug applications approved by US FDA as of 16 - 31 August 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Patients with nonalcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (HCC) suffer from higher surgical morbidity and posthepatectomy liver failure, according to a new Singapore study.
A Singapore study has shown the association of nosocomial spontaneous bacterial peritonitis (N-SBP) with recent antibiotic use, longer hospitalization, more resistant organism and poorer survival among patients with SBP. Moreover, N-SBP and Model for End-stage Liver Disease (MELD) score are predictors of higher mortality in SBP.
Treatment with rifaximin for overt hepatic encephalopathy recurrence in patients on liver transplantation waitlist appears to significantly lessen hospital admissions associated with spontaneous bacterial peritonitis, ascites and variceal bleeding, a recent study has found. Furthermore, it helps reduce requirement for transplant prioritization and prolong time to hospital readmission.
Type 2 diabetes patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis may fare well with long-term use of metformin, as the drug confers marked benefits for transplant-free survival and helps prevent the development of hepatocellular carcinoma (HCC), according to a recent study.
Measurement of spleen stiffness (SS) may be utilized to assess the risk of a hepatic decompensation and may therefore be used a robust screening tool to identify patients who need closer monitoring, suggests a study. In addition, SS can differentiate between acute and chronic or acute on chronic liver damage.
Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
Implementation of the collaborative care in a rheumatoid arthritis (RA) clinic has led to improvements in nonbiologic disease-modifying antirheumatic drugs (nb-DMARDs) optimization, adherence to safety recommendations on nb-DMARD monitoring and detection of adverse drug events in RA patients, according to a Singapore study.
Supplementation with vitamin D appears to help reduce the serum concentration of total and low-density lipoprotein cholesterol and triglyceride but not high-density lipoprotein cholesterol, suggesting its usefulness for mitigating the risk of cardiovascular disease in patients with hypercholesterolaemia, according to the results of a meta-analysis.